Quantcast

Latest Acthar Stories

2014-08-14 16:27:16

- Creates a diversified, high-growth therapeutic portfolio, capable of delivering substantial, sustainable value for shareholders DUBLIN, Aug. 14, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has completed its acquisition of Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) in a cash and stock transaction valued at approximately $5.8 billion. The acquisition is expected to be immediately accretive to Mallinckrodt's...

2014-08-05 23:02:01

A recent regulatory filing exposes that adverse events occurred in 14% of patients taking Acthar in 2013. Spangenberg Shibley & Liber is interested in speaking with anyone who has taken this potentially dangerous prescription drug. Cleveland Ohio (PRWEB) August 05, 2014 Spangenberg Shibley & Liber is interested in speaking with anyone who has taken Acthar, a potentially dangerous prescription drug, and suffered adverse side effects. A recent regulatory filing by Questcor, the...

2014-07-24 08:34:45

Net Sales $279 Million; Increase of 42% over Prior Year Non-GAAP Results ANAHEIM, Calif., July 24, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the second quarter ended June 30, 2014. Three Months Ended Three Months Ended 06/30/14 06/30/13 Percentage Change --------------------- --------------------- ----------------- GAAP Net Sales...

2014-07-11 23:01:56

A recent regulatory filing exposes that the number of adverse events in 2013 reported by patients taking Acthar was almost 14% of prescriptions. Zoll, Kranz & Borgess is investigating this potentially dangerous drug. Toledo, Ohio (PRWEB) July 11, 2014 As reported by the New York Times (Morgenson 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number of severe adverse events such as renal failure, increases in blood sugar, abdominal issues and even death from the...

2014-05-14 08:32:08

- Expands pipeline and broadens platform with next-generation melanocortin peptides - ANAHEIM, Calif., May 14, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has entered into a development collaboration agreement with an undisclosed privately held European company to develop novel melanocortin peptides. The collaboration includes an option to acquire the technology during clinical development. Along with the June 2013 acquisition of Synacthen(®),...

2014-05-05 08:30:03

- Significant clinical response to Acthar was observed in patients experiencing active disease while on conventional SLE maintenance therapies - ANAHEIM, Calif., May 5, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that results from the first modern clinical study examining the use of H.P. Acthar® Gel (repository corticotropin injection) in systemic lupus erythematosus (SLE) has been published in the journal LUPUS. This independent investigator-initiated...

2014-04-28 16:31:16

- Net Sales $227 Million; Increase 68% Year-over-Year - ANAHEIM, Calif., April 28, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the first quarter ended March 31, 2014. Three Months Ended 03/31/14 Three Months Ended 03/31/13 Percentage Change ------------------------------ ------------------------------ ----------------- Net Sales $227.1 Million $135.1...

2014-04-21 08:26:07

- Clinical results appear to correlate with reduction in anti-PLA2R antibodies ANAHEIM, Calif., April 21, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that results from an investigator-initiated clinical study involving two major academic research centers examining the dosing and effectiveness of H.P. Acthar® Gel (repository corticotropin) in 20 patients with nephrotic syndrome due to idiopathic membranous nephropathy (iMN) have been published in the...

2014-04-07 08:29:44

--Questcor Shareholders Receive $30.00 in Cash and 0.897 Mallinckrodt Shares for Each Share of Questcor Common Stock They Own-- DUBLIN and ANAHEIM, Calif., April 7, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals company, and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), a high-growth biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction...

2014-02-25 16:29:30

- Fourth Quarter Net Sales $243 Million; Increase 51% Year-over-Year - ANAHEIM, Calif., Feb. 25, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the fourth quarter and full year ended December 31, 2013. Three Months Ended 12/31/13 Three Months Ended 12/31/12 Percentage Change ------------------------------ ------------------------------ ----------------- Net Sales $242.9...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related